• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Director Clark R Kerry was granted 601 shares, increasing direct ownership by 7% to 9,640 units (SEC Form 4)

    5/16/25 4:14:19 PM ET
    $ELV
    Medical Specialities
    Health Care
    Get the next $ELV alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    CLARK R KERRY

    (Last) (First) (Middle)
    220 VIRGINIA AVENUE

    (Street)
    INDIANAPOLIS IN 46204

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Elevance Health, Inc. [ ELV ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/14/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/14/2025 A 601(1)(2) A $0 9,640 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Deferred stock units accrued under the Elevance Health, Inc. ("Company") Board of Directors Compensation Program.
    2. The deferred stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan.
    Remarks:
    /s/ Kathleen S. Kiefer, Attorney in fact 05/16/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ELV alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ELV

    DatePrice TargetRatingAnalyst
    7/21/2025Buy → Hold
    Argus
    7/18/2025$310.00Outperform → Market Perform
    Leerink Partners
    4/15/2025$529.00Outperform → Neutral
    Robert W. Baird
    3/17/2025$450.00Hold → Buy
    Argus
    1/22/2025$520.00 → $440.00Overweight → Equal-Weight
    Stephens
    10/18/2024Buy → Hold
    Argus
    7/18/2024$646.00 → $530.00Buy → Neutral
    BofA Securities
    6/24/2024$643.00Overweight
    Morgan Stanley
    More analyst ratings

    $ELV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Study Finds Digital Asthma Program Significantly Improves Symptom Control in Adults

      Elevance Health and UC Irvine study underscores potential of digital health tools to reduce asthma burden across U.S. populations A groundbreaking clinical trial led by multidisciplinary researchers found that a digital asthma self-management (DASM) program significantly improved asthma symptom control in adults, with benefits sustained over 12 months. Program participants used everyday devices - like Apple Watch and iPhone – along with a tailored mobile app to help them manage their asthma. The findings represent some of the most compelling evidence to date supporting the use of digital health technologies in asthma care. The virtual, randomized, controlled and decentralized study was

      7/22/25 9:00:00 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health Reports Second Quarter 2025 Results

      2Q 2025 operating revenue of $49.4 billion, up 14.3% from 2Q 2024 2Q 2025 diluted EPS1 of $7.72; adjusted diluted EPS2 of $8.84 Revising FY 2025 adjusted diluted EPS guidance to approximately $30.00 Returned $2.0 billion of capital to shareholders year-to-date Elevance Health, Inc. (NYSE:ELV) reported second quarter 2025 results. "In the second quarter, Elevance Health made meaningful progress in delivering an experience that is simple and personal to those we serve, while advancing our efforts to enhance efficiency across the healthcare system. We are updating our outlook to reflect elevated medical cost trends in ACA and slower rate alignment in Medicaid. While the exter

      7/17/25 6:00:00 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2025 Results on July 17

      Elevance Health (NYSE:ELV) will release second quarter 2025 financial results on July 17, 2025, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 - Access Code - 3972058 (Domestic) 312-470-0178 - Access Code - 3972058 (International) 866-511-1890 - No Access Code (Domestic Replay) 203-369-1945 - No Access Code (International Replay) The replay will be available from 11:30 a.m. EDT on July 17, 2025, until the end of the day on August 15, 2025. The call w

      7/2/25 4:15:00 PM ET
      $ELV
      Medical Specialities
      Health Care

    $ELV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Elevance Health downgraded by Argus

      Argus downgraded Elevance Health from Buy to Hold

      7/21/25 8:26:59 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Elevance Health from Outperform to Market Perform and set a new price target of $310.00

      7/18/25 8:10:27 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Elevance Health from Outperform to Neutral and set a new price target of $529.00

      4/15/25 9:24:40 AM ET
      $ELV
      Medical Specialities
      Health Care

    $ELV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Boudreaux Gail bought $2,438,951 worth of shares (8,500 units at $286.94), increasing direct ownership by 6% to 151,020 units (SEC Form 4)

      4 - Elevance Health, Inc. (0001156039) (Issuer)

      7/18/25 1:42:51 PM ET
      $ELV
      Medical Specialities
      Health Care

    $ELV
    Leadership Updates

    Live Leadership Updates

    See more
    • Elevance Health Appoints Nathan Rich Vice President, Investor Relations

      Elevance Health (NYSE:ELV) announced today the appointment of Nathan Rich as Vice President, Investor Relations, effective November 11, 2024. In this role, Mr. Rich will lead Elevance Health's investor relations efforts, providing strategic leadership to support the company's growth initiatives and strengthen relationships within the investment community. He will also serve as a member of the company's executive leadership team and will report directly to Mark Kaye, Executive Vice President and Chief Financial Officer. Mr. Rich succeeds Stephen Tanal, who now serves as Chief Financial Officer for Elevance Health's Government Health Benefits business. "Nate brings nearly two decades of expe

      11/4/24 9:00:00 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Former Deputy Commissioner of New York State Department of Health Joins Sheppard Mullin

      Nationally Recognized Healthcare Policy Leader Adam Herbst Strengthens the Firm's Regulatory Capabilities for Clients Across the Post-Acute, Aging and Long-Term Care Sectors Sheppard, Mullin, Richter & Hampton LLP is pleased to announce that Adam S. Herbst has joined the firm as a healthcare partner in New York. Most recently, Herbst served as the New York State Department of Health's Deputy Commissioner for Aging and Long Term Care. He is the ninth healthcare partner to join the firm in 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241030758975/en/Adam Herbst (Photo: Business Wire) In joining Sheppard Mullin's industry-l

      10/30/24 12:55:00 PM ET
      $ELV
      Medical Specialities
      Health Care
    • Performant Financial Corporation Announces the Appointment of Dr. Shantanu Agrawal to Its Board of Directors

      Performant Financial Corporation (NASDAQ:PFMT) (Performant), primarily operating as Performant Healthcare Solutions, a leading provider of technology-enabled payment integrity, eligibility, and related analytics services, is proud to announce the appointment of Dr. Shantanu Agrawal, M.D. to its Board of Directors. Dr. Agrawal brings a wealth of expertise and experience in healthcare policy and payment integrity. As Chief Health Officer at Elevance Health (NYSE:ELV), Dr. Agrawal oversees the whole health strategy, including medical policy and clinical quality, as well as the community health strategy and Elevance Health Foundation. Prior to Elevance Health, Dr. Agrawal held numerous execut

      3/6/24 4:30:00 PM ET
      $ELV
      $PFMT
      Medical Specialities
      Health Care
      Other Consumer Services
      Consumer Discretionary

    $ELV
    Financials

    Live finance-specific insights

    See more
    • Elevance Health Reports Second Quarter 2025 Results

      2Q 2025 operating revenue of $49.4 billion, up 14.3% from 2Q 2024 2Q 2025 diluted EPS1 of $7.72; adjusted diluted EPS2 of $8.84 Revising FY 2025 adjusted diluted EPS guidance to approximately $30.00 Returned $2.0 billion of capital to shareholders year-to-date Elevance Health, Inc. (NYSE:ELV) reported second quarter 2025 results. "In the second quarter, Elevance Health made meaningful progress in delivering an experience that is simple and personal to those we serve, while advancing our efforts to enhance efficiency across the healthcare system. We are updating our outlook to reflect elevated medical cost trends in ACA and slower rate alignment in Medicaid. While the exter

      7/17/25 6:00:00 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2025 Results on July 17

      Elevance Health (NYSE:ELV) will release second quarter 2025 financial results on July 17, 2025, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 - Access Code - 3972058 (Domestic) 312-470-0178 - Access Code - 3972058 (International) 866-511-1890 - No Access Code (Domestic Replay) 203-369-1945 - No Access Code (International Replay) The replay will be available from 11:30 a.m. EDT on July 17, 2025, until the end of the day on August 15, 2025. The call w

      7/2/25 4:15:00 PM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health Reports First Quarter 2025 Results

      1Q 2025 operating revenue of $48.8 billion, up 15.4% from 1Q 2024 1Q 2025 adjusted operating gain1 of $3.3 billion, up 4.1% from 1Q 2024 1Q 2025 diluted EPS2 of $9.61; adjusted diluted EPS1 of $11.97 Reaffirm FY 2025 adjusted diluted EPS1 of $34.15 to $34.85 Returned $1.3 billion of capital to shareholders in 1Q 2025 Elevance Health, Inc. (NYSE:ELV) reported first quarter 2025 results. "At Elevance Health, our purpose—to improve the health of humanity—drives everything we do. In the first quarter, we made measurable progress reimagining the healthcare experience with personalized support, real-time digital solutions, and a whole-health model that improves outcomes and reduces co

      4/22/25 6:00:00 AM ET
      $ELV
      Medical Specialities
      Health Care

    $ELV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Elevance Health Inc.

      SC 13G/A - Elevance Health, Inc. (0001156039) (Subject)

      11/14/24 1:22:35 PM ET
      $ELV
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Elevance Health Inc.

      SC 13G - Elevance Health, Inc. (0001156039) (Subject)

      2/14/24 10:02:59 AM ET
      $ELV
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Elevance Health Inc.

      SC 13G - Elevance Health, Inc. (0001156039) (Subject)

      2/14/23 12:37:59 PM ET
      $ELV
      Medical Specialities
      Health Care

    $ELV
    SEC Filings

    See more
    • SEC Form 10-Q filed by Elevance Health Inc.

      10-Q - Elevance Health, Inc. (0001156039) (Filer)

      7/17/25 3:09:00 PM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Elevance Health, Inc. (0001156039) (Filer)

      7/17/25 6:03:40 AM ET
      $ELV
      Medical Specialities
      Health Care
    • SEC Form 11-K filed by Elevance Health Inc.

      11-K - Elevance Health, Inc. (0001156039) (Filer)

      6/24/25 2:34:13 PM ET
      $ELV
      Medical Specialities
      Health Care

    $ELV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Boudreaux Gail bought $2,438,951 worth of shares (8,500 units at $286.94), increasing direct ownership by 6% to 151,020 units (SEC Form 4)

      4 - Elevance Health, Inc. (0001156039) (Issuer)

      7/18/25 1:42:51 PM ET
      $ELV
      Medical Specialities
      Health Care
    • Director Strable-Soethout Deanna D was granted 601 shares, increasing direct ownership by 58% to 1,646 units (SEC Form 4)

      4 - Elevance Health, Inc. (0001156039) (Issuer)

      5/16/25 4:19:25 PM ET
      $ELV
      Medical Specialities
      Health Care
    • Director Schneider Ryan M. was granted 601 shares, increasing direct ownership by 10% to 6,600 units (SEC Form 4)

      4 - Elevance Health, Inc. (0001156039) (Issuer)

      5/16/25 4:18:55 PM ET
      $ELV
      Medical Specialities
      Health Care